3 min read
Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology
Geneva, Switzerland, and Newark, CA, OCTOBER 17, 2019 – Selexis SA and Teneobio, Inc. announced today that they have...